Published in Front Pharmacol on October 28, 2014
Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disorders. J Venom Anim Toxins Incl Trop Dis (2015) 0.76
The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries. Front Pharmacol (2014) 0.98
Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front Pharmacol (2014) 0.92
Osteoporosis and alzheimer pathology: Role of cellular stress response and hormetic redox signaling in aging and bone remodeling. Front Pharmacol (2014) 0.91
HSV-1 and Alzheimer's disease: more than a hypothesis. Front Pharmacol (2014) 0.91
Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer's disease. Front Pharmacol (2014) 0.89
Nutraceuticals in cognitive impairment and Alzheimer's disease. Front Pharmacol (2014) 0.87
From industrial research to academic discoveries, toward a new concept of partnership: the Biomathics model. Front Pharmacol (2014) 0.87
Age-related changes of protein SUMOylation balance in the AβPP Tg2576 mouse model of Alzheimer's disease. Front Pharmacol (2014) 0.86
Cellular stress response, redox status, and vitagenes in glaucoma: a systemic oxidant disorder linked to Alzheimer's disease. Front Pharmacol (2014) 0.85
Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges. Front Pharmacol (2014) 0.82
Vitamin D supplements: a novel therapeutic approach for Alzheimer patients. Front Pharmacol (2014) 0.80